Clinical trials: Stage I Skin Cancer
Advanced Cancer, Gastric Cancer
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients…
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- GEN602 (NCT03775525)
- Testing
- GZ17-6.02, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Genzada Pharmaceuticals USA, Inc.
Breast Cancer, Stage 0, Colorectal Cancer Stage I
Virtual Rehabilitation for Cancer Survivors
Pragmatic hybrid type 1 effectiveness-implementation (E-I) trial of a virtual cancer rehabilitation program: The study team will conduct a multi-center hybrid type I effectiveness-implementation study to examine the clinical…
- Conditions
- Breast Cancer, Stage 0, Colorectal Cancer Stage I, Head and Neck Cancer Stage I, Lymphoma
- Trial name
- NCT05898789
- Testing
- CaRE@Home intervention
- Where
- Canada
- Volunteers
- 388 people
- Sponsor
- University Health Network, Toronto
Cancer
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
This study is a Phase 1 dose-escalation open-label study to determine the recommended Phase II dose (RP2D) and regimen for the combination of the orally administered MEK inhibitor GSK1120212 and the orally administered AKT kinase…
- Trial name
- NCT01138085
- Testing
- GSK1120212, GSK2141795
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer
The purpose of this study is to see how safe Androderm® (the study drug) is at three different doses in subjects with early hormone refractory prostate cancer.
- Trial name
- NCT01187485
- Testing
- Androderm® 2.5mg, Androderm® 5.0mg, Androderm® 7.5mg
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Chicago
Breast Cancer, Breast - Female
CARE (Chemotherapy Alopecia REduction)
The goal of this research study is to determine if the DigniCap Scalp Cooling System can help prevent chemotherapy-induced hair loss in Black patients.
- Conditions
- Breast Cancer, Breast - Female, Breast Cancer Stage I, Breast Cancer Stage II
- Trial name
- CARE (NCT07201389)
- Testing
- Scalp Cooling by DigniCap
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- George Washington University
Actinic Keratoses
Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005
The purpose of this study is to determine the extent of systemic absorption of PEP005 when applied topically for the treatment of actinic keratoses.
- Trial name
- NCT00544258
- Testing
- PEP005
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- Peplin
Stage III or Stage IV Melanoma
Safety Study of CADI-05 in Patients With Advanced Stage Melanoma
This study examines the safety of treating patients with advanced stage melanoma with the vaccine CADI-05. In addition, preliminary data regarding the clinical response and immune response will be collected.
- Trial name
- NCT00675727
- Testing
- CADI-05
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cadila Pharnmaceuticals
Cancer, Solid Tumor
Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)
The present study has 5 parts. In Parts A and A1, the dose of intravenous (IV) pembrolizumab (MK-3475) will be escalated from 1 to 10 mg/kg to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for…
- Trial name
- KEYNOTE-001 (NCT01295827)
- Testing
- Pembrolizumab
- Volunteers
- 1,260 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Carcinoma, Breast Cancer Stage I
A New Tool to Promote Patient's Engagement in Their Healthcare Process
Women diagnosed with early-stage breast cancer need to make a decision about the therapeutic treatment to undertake. Since multiple factors can influence this decision, it is necessary to develop a decision-making support tool to…
- Conditions
- Breast Carcinoma, Breast Cancer Stage I, Breast Cancer Stage II
- Trial name
- NCT06762496
- Testing
- Healthcare professionals, Patients PDA group, Patients control group
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- European Institute of Oncology
Breast Cancer
Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
The goal of this clinical research study is to find the highest tolerable dose of seliciclib that can be given in combination with liposomal doxorubicin to patients with metastatic breast cancer.
- Trial name
- NCT01333423
- Testing
- Liposomal Doxorubicin, Seliciclib
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy, using exemestane or anastrozole, may fight breast cancer by reducing the production of estrogen.
- Trial name
- NCT00066573
- Testing
- anastrozole, exemestane
- Where
- 39 sites in Canada
- Volunteers
- 7,576 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer, Depression
Study of Health Promotion in Patients With Early-Stage Breast or Prostate Cancer
RATIONALE: Telephone counseling by a nutritionist and a personal trainer may improve physical function and quality of life in patients who have early-stage breast cancer or prostate cancer.
- Conditions
- Breast Cancer, Depression, Fatigue, Malnutrition
- Trial name
- NCT00037024
- Testing
- fatigue assessment and management, nutritional support, physical therapy
- Where
- United States
- Sponsor
- Duke University
Advanced Solid Tumor, RAS Mutation
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients…
- Conditions
- Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
- Trial name
- NCT05831995
- Testing
- ABM-168
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- ABM Therapeutics Corporation
Breast Cancer
Studying Tumor Tissue Samples From Patients With Early-Stage Breast Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00899639
- Sponsor
- Rutgers, The State University of New Jersey
Breast Cancer
Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer
RATIONALE: A breath test that measures enzymes may be effective in identifying women in whom tamoxifen may not be effective. PURPOSE: This clinical trial is studying a breath test to see how well it works in women receiving…
- Trial name
- NCT00873366
- Testing
- dextromethorphan hydrobromide, tamoxifen citrate, high performance liquid chromatography
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Mayo Clinic
Solid Tumor
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
In phase Ia study, the safety and tolerability of SI-B003 in patients with recurrent or metastatic solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT04606472
- Testing
- SI-B003
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
HER2 Positive Breast Carcinoma, Stage I Breast Cancer AJCC v7
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
This phase II trial studies the side effects and how well cyclophosphamide, paclitaxel, and trastuzumab work when given after surgery in treating patients with stage I-II human epidermal growth factor receptor (HER2/neu) positive…
- Conditions
- HER2 Positive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
- Trial name
- NCT02654119
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Nebraska
Breast Cancer, Kidney Cancer
Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of cancer. PURPOSE: This phase I trial is studying the side effects and best dose of interferon alfa in treating patients with stage IV…
- Conditions
- Breast Cancer, Kidney Cancer, Lymphoma, Melanoma
- Trial name
- IFNa (NCT00276536)
- Testing
- recombinant interferon alpha-1b, IFN
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- The Cleveland Clinic
Breast Cancer
Vaccine Therapy in Treating Women With Metastatic Breast Cancer
RATIONALE: Vaccines made from breast cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccines made from breast cancer cells in treating women with…
- Trial name
- NCT00003184
- Testing
- BCG vaccine, CD80 breast cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- Providence Cancer Center, Earle A. Chiles Research Institute
Ductal Breast Carcinoma in Situ, Breast Cancer, Stage I
Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors
This randomized double-blind clinical trial studied the effect of oral omega-3 fatty acid on atrophic vaginitis in postmenopausal breast cancer survivors (N=52).
- Conditions
- Ductal Breast Carcinoma in Situ, Breast Cancer, Stage I, Breast Cancer, Stage II, Breast Cancer, Stage III
- Trial name
- NCT02150525
- Testing
- omega-3 fatty acid, Questionnaire administration
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.